Florian Klein

Florian Klein

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2018 in Nature
Verified
Journal Article
Closed access
PDF file
PMPilar Mendoza
Pilar Mendoza
HGHenning Gruell
Henning Gruell
LNLilian Nogueira
Lilian Nogueira
JPJoy A. Pai
Joy A. Pai
ABAllison L. Butler
Allison L. Butler
MNMichel C. Nussenzweig
Michel C. Nussenzweig

16 January 2017 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MCMarina Caskey
Marina Caskey
TSTill Schoofs
Till Schoofs
HGHenning Gruell
Henning Gruell
ASAllison Settler
Allison Settler
TKTheodora Karagounis
Theodora Karagounis
FKFlorian Klein
Florian Klein

19 January 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
HGHenning Gruell
Henning Gruell
KVKanika Vanshylla
Kanika Vanshylla
PTPinkus Tober-Lau
Pinkus Tober-Lau
DHDavid Hillus
David Hillus
PSPhilipp Schommers
Philipp Schommers
FKFlorian Klein
Florian Klein
The Omicron variant of SARS-CoV-2 is causing a rapid increase in infections across the globe. This new variant of concern carries an unusually high number of mutations in key epitopes of neutralizing antibodies on the viral spike glycoprotein, suggesting potential immune evasion. Here we assessed serum neutralizing capacity in longitudinal cohorts of vaccinated and convalescent individuals, as well as monoclonal antibody activity against Omicron using pseudovirus neutralization assays. We report a near-complete lack of neutralizing activity against Omicron in polyclonal sera from individuals vaccinated with two doses of the BNT162b2 COVID-19 vaccine and from convalescent individuals, as well as resistance to different monoclonal antibodies in clinical use. However, mRNA booster immunizations in vaccinated and convalescent individuals resulted in a significant increase of serum neutralizing activity against Omicron. This study demonstrates that booster immunizations can critically improve the humoral immune response against the Omicron variant.

1 August 2020 in Cell
Verified
Journal Article
Open access
CKChristoph Kreer
Christoph Kreer
MZMatthias Zehner
Matthias Zehner
TWTimm Weber
Timm Weber
MEMeryem S. Ercanoglu
Meryem S. Ercanoglu
LGLutz Gieselmann
Lutz Gieselmann
FKFlorian Klein
Florian Klein
The SARS-CoV-2 pandemic has unprecedented implications for public health, social life, and the world economy. Because approved drugs and vaccines are limited or not available, new options for COVID-19 treatment and prevention are in high demand. To identify SARS-CoV-2-neutralizing antibodies, we analyzed the antibody response of 12 COVID-19 patients from 8 to 69 days after diagnosis. By screening 4,313 SARS-CoV-2-reactive B cells, we isolated 255 antibodies from different time points as early as 8 days after diagnosis. Of these, 27 potently neutralized authentic SARS-CoV-2 with IC100 as low as 0.04 μg/mL, showing a broad spectrum of variable (V) genes and low levels of somatic mutations. Interestingly, potential precursor sequences were identified in naive B cell repertoires from 48 healthy individuals who were sampled before the COVID-19 pandemic. Our results demonstrate that SARS-CoV-2-neutralizing antibodies are readily generated from a diverse pool of precursors, fostering hope for rapid induction of a protective immune response upon vaccination.

26 September 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
YBYotam Bar-On
Yotam Bar-On
HGHenning Gruell
Henning Gruell
TSTill Schoofs
Till Schoofs
JPJoy A. Pai
Joy A. Pai
LNLilian Nogueira
Lilian Nogueira
MNMichel C. Nussenzweig
Michel C. Nussenzweig

1 April 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MCMarina Caskey
Marina Caskey
FKFlorian Klein
Florian Klein
MNMichel C. Nussenzweig
Michel C. Nussenzweig